Intellia Therapeutics (NTLA) Non-Current Deferred Tax Liability (2022 - 2025)

Intellia Therapeutics (NTLA) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $517.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Non-Current Deferred Tax Liability rose 861.34% year-over-year to $517.2 million; the TTM figure through Dec 2025 stood at $517.2 million (up 861.34% YoY), while the FY2025 annual figure was $517.2 million, up 861.34% from the prior year.
• Non-Current Deferred Tax Liability grew to $517.2 million in Q4 2025 per NTLA's latest filing, from $53.8 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $517.2 million in Q4 2025 and bottomed at $53.8 million in Q4 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $314.8 million across 4 years, with a median of $344.2 million in 2022.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability plunged 85.29% — and 2025, when it surged 861.34%.
• Intellia Therapeutics' Non-Current Deferred Tax Liability stood at $322.6 million in 2022, then increased by 13.39% to $365.8 million in 2023, then slumped by 85.29% to $53.8 million in 2024, then soared by 861.34% to $517.2 million in 2025.
• Business Quant data shows NTLA's Non-Current Deferred Tax Liability at $517.2 million in Q4 2025, $53.8 million in Q4 2024, and $365.8 million in Q4 2023.